DNMT3A and lung carcinoma: Furthermore, abnormal activation of DNMT3A and DNMT3B is closely related to the early occurrence of lung cancer, and their inhibitors (such as azacitidine and decitabine) have been approved for use in hematological tumors and are being explored for epigenetic therapy in lung cancer (142).